Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 (minocycline HCl) Extended Release Capsules Compared to Placebo for the Treatment of Inflammatory Lesions of Rosacea over 16 weeks

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 (minocycline HCl) Extended Release Capsules Compared to Placebo for the Treatment of Inflammatory Lesions of Rosacea over 16 weeks

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Minocycline (Primary)
  • Indications Erythema; Rosacea
  • Focus Therapeutic Use
  • Sponsors Dr Reddys Laboratories

    • Most Recent Events

    • 28 Mar 2024 According to a Fortress Biotech media release, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) filing for DFD-29 earlier this month and look forward to the Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024.
    • 02 Jan 2024 According to a Journey Medical Corporation media release,company a has entered into a credit facility with an affiliate of SWK Holdings Corporation a specialized finance company with a focus on the global healthcare sector, providing for borrowings of up to $20 million and this The funding will support general corporate purposes, as well as anticipated expenses for DFD-29, including an upcoming New Drug Application submission pending FDA approval.
    • 30 Mar 2023 According to a Fortress Biotech media release, an FDA approval decision is anticipated in the second half of 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top